Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Sign Out
Sign In
Register
Follow the Journey
Companies On The Road
Arcadis DPS Group
C2 Pharma
CAI
EcoLab
Environmental Systems Corporation
Federal Equipment Company
Globyz Biopharma Services
Grifols
Integrity
Nu-Tek BioSciences
PHARMALEX
Waters Corporation
Follow the Journey
Companies On The Road
ABS
aCGT Vector
Alconox Inc.
Andelyn Biosciences
Arranta Bio
Avid Bioservices
BDD
BIOVECTRA
DPS Group
Dynamk Capital
Environmental Systems Corporation
Federal Equipment Company
Genesis AEC
Globyz Biopharma Services
Grifols Partnership
IDT Biologika
Inceptor Bio
IPS-Integrated Project Services
Kineticos Life Sciences
MilliporeSigma
Montana BioScience Alliance
Olon
Rentschler Biopharma
SanaClis
Scorpion Biological Services
Secant Group
Tapemark
VITRONIC
Follow the Journey
Companies On The Road
AES Clean Technology
Altis Biosystems
Arranta Bio
Avara Pharmaceutical Services
Avid Bioservices
BioVectra
Centaur BPS
Dynamk Capital
ECRI
Evolve Biologics
Federal Equipment Company
Globyz
Inceptor Bio
IPS-Integrated Project Services
Olon
Pii
Polpharma Biologics
PPD
RoosterBio
SanaClis
Sanofi AIS
SGD Pharma
SPI Pharma
TriRx Pharmaceutical Services
Yourway
Dashboard
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Magazine
Archive
Reports
Nice Insight Reports
2022 Sterile
2023 Cell & Gene Therapy
2023 mAb and Recombinant Protein
2024 API
2024 OSD
2024 ADC
2024 mRNA
2024 Mammalian Cell Culture
2024 Microbial Cell Culture
2024 Plasmids
2024 Gene Therapy
2024 Cell Therapy
2024 Sterile
Community
Company A to Z
Follow the Journey
Companies On The Road
Follow The Artist
Follow the Journey
Companies On The Road
More+
Staffing
Media Kit
GSK
60 Articles Available
1
3
Can't find what you're looking for? Try our
advanced search
.
Unmet Needs
In which orphan spaces or unmet medical needs do you think we will see the next treatment innovations?
PAO-06-022--RT-01
Industry Challenges
What do you consider the biggest challenge that the pharma/biopharma industry currently faces?
O-06-022--RT-01
Expansion
GSK Unveils Plan for One of Europe’s Largest Life Science Campuses in Stevenage
PR-M07-21-08
Collaboration
ViiV Healthcare and Halozyme Enter Global Collaboration for ENHANZE® Drug Delivery Technology to Enable Development of “Ultra Long-Acting” Medicines for HIV
PR-M06-21-032
COVID-19 Vaccine
Sanofi and GSK COVID-19 Vaccine Candidate Demonstrates Strong Immune Responses Across All Adult Age Groups in Phase 2 Trial
PR-M05-21-011
Clinical Trials
Lilly, Vir Biotechnology and GSK Announce Positive Topline Data From the Phase 2 Blaze-4 Trial Evaluating Bamlanivimab With Vir-7831 in Low-risk Adults With Covid-19
PR-M04-21-004
Agreements and Partnerships
GSK to Support Manufacture of Novavax’ COVID-19 Vaccine
PR-M04-21-002
COVID-19 Vaccine
Sanofi and GSK to Support COVAX with 200 Million Doses of COVID-19 Vaccine
PR-M10-20-18
FDA Approval
FDA Approves GSK’s BLENREP for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
PR-M08-20-NI-11
COVID-19 Vaccine Funding
Sanofi and GSK Selected for Operation Warp Speed to Supply United States Government with 100 Million Doses of COVID-19 Vaccine
PR-M08-20-NI-05
COVID-19 Vaccine Collaboration
GSK and Medicago Announce Collaboration to Develop a Novel Adjuvanted COVID-19 Candidate Vaccine
PR-M07-20-NI-009
HIV
ViiV Healthcare’s Injectable Formulation Dosed Every Two Months Shows Higher Efficacy than Daily Oral PrEP
PR-M05-20-NI-034
FDA Approves GSK's Zejula
PR-M05-20-NI-014
Sanofi and GSK to Join Forces in COVID-19 Vaccine Collaboration
PR-M04-20-NI-020
GSK's Asthma Biologic Approved
PR-M04-20-NI-007
M&A
Bora Pharmaceuticals to Acquire GSK Mississauga-based Facility
PR-M03-20-NI-018
Partnership
Immatics and GSK Partner to Develop Novel Adoptive Cell Therapies
PR-M02-20-NI-025
Vaccine
CEPI and GSK Collaborate to Develop a Vaccine for Coronavirus
PR-M02-20-NI-001
Vaccine
GSK Candidate Vaccine Demonstrates Sustained Level of Protection Against Active Pulmonary Tuberculosis
PR-M10-19-NI-040
Divest
GSK Agrees to Divest Rabies and Tick-Borne Encephalitis Vaccines to Bavarian Nordic
PR-M10-19-NI-038
FDA Approval
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
PR-M10-19-NI-035
Investment
GSK Invests $120 million in Next-generation US Biopharmaceutical Manufacturing Facility
R-M09-19-NI-051
M&A
Avalon Ventures and COI Pharmaceuticals Announce Acquisition of Sitari Pharmaceuticals by GSK
PR-M09-19-NI-034
Licensing
Ionis Licenses Hepatitis B Program to GSK
PR-M08-19-NI-085
1
3
»
.svg)